### **Company Overview** Suven Life Sciences Ltd is a **clinical-stage biopharmaceutical company** headquartered in Hyderabad, India, exclusively focused on the **discovery and development of New Chemical Entities (NCEs)** for central nervous system (CNS) disorders with high unmet medical needs. Founded in 1989, the company transitioned from a contract research and manufacturing services (CRAMS) model to a dedicated CNS-focused innovation platform in the early 2000s. This strategic pivot highlights its long-term commitment to pioneering neurological therapeutics. Suven operates through its wholly owned U.S. subsidiary, **Suven Neurosciences, Inc.**, established in 2015, which leads clinical development from Phase 2 onward under U.S. regulatory pathways. The company is listed on the BSE and National Stock Exchange (NSE) and is recognized as the only Indian pharmaceutical firm solely dedicated to CNS NCE development. --- ### **Therapeutic Focus & Strategic Vision** Suven’s R&D is centered on **G protein-coupled receptor (GPCR)** targets and focuses on addressing complex CNS conditions, including: - Alzheimer’s disease and related dementias - Narcolepsy and excessive daytime sleepiness (EDS) - Major Depressive Disorder (MDD) - Cognitive impairment - Psychosis and schizophrenia - Chronic pain and inflammation Its strategic objective is to develop **first-in-class or best-in-class therapies** with differentiated mechanisms of action, supported by robust preclinical and clinical evidence, favorable safety profiles, and potential for accelerated regulatory pathways. The company employs a **“fail-fast, learn-fast” strategy** to optimize clinical development, reduce costs, and improve success rates through early regulatory engagement, shorter trials, and biomarker-guided designs. --- ### **Clinical Pipeline (as of Nov 2025)** #### **1. SUVN-502 (Masupirdine)** – **Phase 3** - **Indication**: Agitation in Alzheimer’s-type dementia - **Mechanism**: Selective 5-HT6 receptor antagonist - **Status**: Global Phase 3 trial (NCT05397639) ongoing in North America and Europe; over **43% of 375 planned patients enrolled** - **Progress**: Expected completion by **end of 2026**, with topline data anticipated in **Q1/Q2 2027** - **Differentiation**: Non-sedating, improved safety profile vs. antipsychotics; potential for **Breakthrough Therapy Designation (BTD)** - **Background**: Repositioned from cognitive impairment due to strong secondary signals in agitation and aggression in prior Phase 2 trials --- #### **2. SUVN-G3031 (Samelisant)** – **Phase 3 (Preparation Stage)** - **Indication**: Excessive Daytime Sleepiness (EDS) in narcolepsy - **Mechanism**: Potent and selective Histamine H3 receptor inverse agonist - **Status**: Phase 2 trial completed (NCT04072380), showing **significant improvement in EDS with no abuse potential or serious cardiovascular risks** - **Next Steps**: - **Phase 3 pivotal trial** initiation planned by **end of FY26 (Q2 2026)** - Potential **orphan drug designation** in multiple regions due to rare disease status - **Expansion Potential**: Future trials in **cataplexy, idiopathic hypersomnia, and Prader-Willi syndrome** being explored --- #### **3. SUVN-911 (Ropanicant)** – **Phase 2B** - **Indication**: Major Depressive Disorder (MDD) - **Mechanism**: Selective α4β2 nicotinic acetylcholine receptor antagonist - **Status**: Ongoing **double-blind, placebo-controlled Phase 2B trial (CTP2S2911A4B2)** in the U.S. with ~195 patients across 35 sites; started in July 2025 - **Expected Completion**: End of 2026 - **Differentiation**: - Rapid onset of action - No sexual dysfunction - **Pro-cognitive effects** - Favorable safety profile - **Potential**: Eligible for **Breakthrough Therapy Designation** - **Phase 2A**: Open-label study completed ahead of schedule, demonstrating safety and early efficacy signals --- #### **4. SUVN-D4010 (Usmarapride)** – **Pre-Phase 2** - **Indication**: Cognitive impairment in depression and Alzheimer’s - **Mechanism**: Selective 5-HT4 receptor partial agonist - **Status**: Phase 1 completed under U.S. IND (NCT02575482); safe, well-tolerated, once-daily dosing - **Next Steps**: **Phase 2 proof-of-concept double-blind study** planned for **2026** - **Potential**: First-in-class candidate for cognitive dysfunction; supported by FDA pre-IND feedback --- #### **5. SUVN-I6107** – **Phase 1 (Ongoing)** - **Indication**: Cognitive disorders in neurodegenerative diseases (e.g., Alzheimer’s, schizophrenia) - **Mechanism**: Potent and selective **M1 muscarinic receptor positive allosteric modulator (M1 PAM)** - **Status**: Phase 1 trial (NCT06705088) initiated in the U.S. in 2024 - **Single Ascending Dose (SAD)** phase completed - **Multiple Ascending Dose (MAD)** phase ongoing - **Anticipated Completion**: **H1 2026** - **Differentiation**: Robust procognitive effects in animal models; **no cholinergic side effects** (e.g., salivation, GI disturbances) observed at therapeutic doses - **Development Strategy**: Phase 1 includes **early evaluation of translational biomarkers** to guide future Phase 2 design --- ### **Preclinical & Research Pipeline** Suven maintains **seven research-stage projects** targeting broader CNS and neurological indications, including: - **M4 PAMs** for psychosis (novel, orally bioavailable compounds with high selectivity over M2 receptors) - **Dual 5-HT2A antagonist / 5-HT1A agonists** for bipolar disorder and treatment-resistant depression - **P2X7 antagonists** for chronic pain and inflammation (lead series selected with favorable safety and efficacy in preclinical models) - **5-HT1A agonists** for treatment-resistant depression and sleep disorders - **Non-brain-penetrant M1 PAMs** for gastrointestinal motility disorders These programs reflect Suven’s deep expertise in GPCR pharmacology and commitment to building a **sustainable, diversified pipeline**. --- ### **Intellectual Property & Regulatory Strategy** As of Nov 2025, Suven holds **17 additional patents granted**, bringing its **total global IP portfolio to over 300 patents** across strategic jurisdictions including the **U.S., Europe, Japan, India, Australia, China, and Brazil**. The company retains **full global IP rights** for all its clinical-stage assets, enhancing monetization potential. It actively engages regulatory agencies (e.g., FDA) through: - **Pre-IND meetings** - **End-of-Phase-2 (EOP2) discussions** - Design alignment for registrational trials This regulatory agility supports accelerated and scientifically robust clinical development. --- ### **Financial & Operational Updates** - **Funding**: Raised **₹857 crore (~$103 million)** via convertible warrants in May 2025 to fund R&D, clinical trials, and infrastructure. - **Cash Runway**: Strengthened balance sheet to support **24–36 months of operations**, critical during this pivotal data-readout period. - **New R&D Facility**: Constructing a **state-of-the-art R&D center in Chandapur, Sangareddy**, equipped with advanced technologies to support complex CNS drug discovery and development. - **Manufacturing**: Planning in-house **Phase 3 drug substance and drug product manufacturing** for Ropanicant and other candidates. --- ### **Collaboration & Monetization Strategy** Suven is actively seeking **strategic partnerships, out-licensing deals, or co-development agreements**, particularly for: - **Masupirdine (SUVN-502)** – Given its global Phase 3 status - **Samelisant (SUVN-G3031)** – With strong Phase 2 data and orphan potential - **Ropanicant (SUVN-911)** – As a first-in-class MDD candidate The company aims to **leverage external capital and expertise** while retaining optionality in key markets.